Juan Graham

This profile gathers the share dealings of Juan Graham across 2 companies, led by Kyntra Bio, Inc. and Perspective Therapeutics, Inc. In total, 35 filings cover trades dated from 7 September 2021 to 28 March 2025.

Both buying and selling appear: 1 purchase worth €69k, against 12 sales worth €319k. Sales outweigh purchases by €250k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 22 share grants. In 2025 alone, the filings show 1 purchase and no sales.

On 1 April 2025 came the latest disclosure, an open-market purchase for €69k in Perspective Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.